Nona launches AI-driven antibody discovery platform

Nona Biosciences (Nasdaq: NONA) has introduced Hu-mAtrIx, an artificial intelligence (AI)-assisted drug discovery platform designed to accelerate the identification and development of antibody-based therapies.

The new platform integrates artificial intelligence with Nona’s proprietary Harbour Mice technology, allowing researchers to streamline antibody discovery for neurodegenerative, metabolic, and other diseases. The system is designed to shorten drug development timelines and improve efficiency by leveraging AI to optimize antibody selection and engineering.

Hu-mAtrIx enables the analysis of extensive libraries of human antibody sequences to identify candidates with optimal target specificity and binding affinity. The platform can also predict key properties such as stability, manufacturability, and immunogenicity, helping to reduce development risks early in the process.